SKYE

Skye Bioscience, Inc. (SKYE) - Q1 2025 10-Q Summary

Business Context and Reporting Period

This report covers the quarterly period ended March 31, 2025. Skye Bioscience, Inc. is a clinical-stage biotechnology company developing next-generation molecules to treat obesity and related conditions. The company has not yet generated revenue and is focused on advancing its lead candidate, nimacimab, a peripherally restricted negative allosteric modulating antibody targeting the CB1 receptor. The company is currently conducting the CBeyond™ Phase 2a clinical trial.

Key Financial Metrics

Material Changes vs. Prior Period

• Increased R&D Spend: R&D expenses surged by 270% ($5.25M increase) year-over-year. This was driven by increased clinical trial site and patient costs for the nimacimab Phase 2a study, a $2.53M increase in contract manufacturing costs for drug substance and product resupply, and higher discovery research costs.
• Net Loss Expansion: Net loss more than doubled from $5.02M in Q1 2024 to $11.10M in Q1 2025, primarily due to the acceleration of clinical development activities.
• Investing Activities: The company utilized $12.8M in cash to purchase short-term investments (U.S. Treasury Obligations) in Q1 2025, compared to a net inflow of $1.14M in Q1 2024 from the sale of a real estate asset.
• Interest Income: Interest income increased by 45% to $619,054 due to higher yields on cash balances and short-term investments.
• Legal Contingency: The estimated legal contingency for the Wendy Cunning vs. Skye Bioscience, Inc. case stands at $1,913,003 as of March 31, 2025. This reflects a reduction from prior estimates following a Ninth Circuit Court of Appeals decision in October 2024 that vacated a previous judgment and remanded the case for a new trial.

Guidance, Outlook, and Risks

• Clinical Outlook: The company anticipates providing a top-line readout from the CBeyond™ Phase 2a study late in Q3 or early Q4 2025. A protocol extension to 52 weeks has been approved by the IRB to assess long-term safety and efficacy.
• Liquidity Runway: Management believes current cash resources ($59.2M in liquidity) are sufficient to fund projected operations for at least 12 months from the filing date. This runway supports the completion of Phase 2a data readout, manufacturing for future studies, and planning for a Phase 2b dose-ranging study.
• Capital Resources: The company has an At-The-Market (ATM) equity offering agreement allowing for the sale of up to $100M of common stock, though no shares have been sold under this agreement as of the filing date.
• Risks:
  • Legal Uncertainty: The outcome of the retrial in the Cunning lawsuit remains uncertain, and the final loss amount could change in the near term.
  • Development Risk: The company has no approved products and relies on the success of nimacimab. Clinical trials are costly, time-consuming, and subject to failure.
  • Macroeconomic Factors: Potential supply chain disruptions, inflation, and geopolitical tensions could impact operations and clinical trial timelines.

Key Facts for Investor Verification

• Cash Burn Rate: Verify the sustainability of the ~$9.2M quarterly operating cash burn against the $59.2M liquidity position to confirm the 12-month runway assertion.
• Legal Exposure: Monitor the status of the Cunning retrial scheduled for September 2025 and any updates to the $1.91M accrued legal contingency.
• Clinical Milestones: Track the timeline for the CBeyond™ Phase 2a top-line data readout (expected late Q3/early Q4 2025) and the initiation of the 52-week extension.
• Capital Needs: Assess the likelihood of future dilution given the company's lack of revenue and the potential need for additional funding beyond the current 12-month horizon.
• Investment Allocation: Confirm the yield and maturity profile of the $12.8M in newly purchased short-term investments.